- Home
- URGN
URGN
UroGen Pharma Ltd.
as 01-17-2025 4:00pm EST
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RA'ANANA |
| Market Cap: | 465.9M | IPO Year: | 2017 |
| Target Price: | $44.50 | AVG Volume (30 days): | 487.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.78 - $20.70 | Next Earning Date: | 03-13-2025 |
| Revenue: | $89,363,000 | Revenue Growth: | 15.64% |
| Revenue Growth (this year): | 13.39% | Revenue Growth (next year): | 45.06% |
Latest UroGen Pharma Ltd. News
URGN Breaking Stock News: Dive into URGN Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
Simply Wall St.
19 days ago
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)
Business Wire
a month ago
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
Business Wire
a month ago
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
Zacks
2 months ago
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade
Business Wire
2 months ago
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
Clinical Trials Arena
2 months ago
UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment
Compare URGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "URGN UroGen Pharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.